EcoDrugPlus

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSNFUG00015000626
Gene Symbol: LOC107375819
3 Cross references
209 Possible Orthologues:

Equilibrative Nucleoside Transporter 2-Like

Ensembl ID : ENSNFUG00015003199
Gene Symbol: LOC107376754
3 Cross references
199 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSNFUG00015010558
Gene Symbol: ERBB3
1 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSNFUG00015025281
Gene Symbol: ERBB4
1 Cross references
3 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSNFUG00015003347
Gene Symbol: ERBB4
1 Cross references
230 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSNFUG00015002138
Gene Symbol: ESR1
1 Cross references
215 Possible Orthologues:

Estrogen Receptor 2

Ensembl ID : ENSNFUG00015018519
Gene Symbol: ESR2
3 Cross references
208 Possible Orthologues:

Estrogen Receptor 2a

Ensembl ID : ENSNFUG00015001117
Gene Symbol: ESR2A
1 Cross references
198 Possible Orthologues:

Estrogen-Related Receptor Gamma

Ensembl ID : ENSNFUG00015007933
Gene Symbol: LOC107381220
3 Cross references
198 Possible Orthologues:

Exportin 1

Ensembl ID : ENSNFUG00015016172
Gene Symbol: XPO1
1 Cross references
224 Possible Orthologues:

Exportin-1

Ensembl ID : ENSNFUG00015000944
Gene Symbol: LOC107375520
3 Cross references
213 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSNFUG00015003910
Gene Symbol: FDFT1
3 Cross references
220 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).